Ascending Multiple-Dose Study of Brivanib Alaninate in Combination With Chemotherapeutic Agents in Subjects With Advanced Cancers

Completed · Phase 1

Conditions studied: Advanced Cancer

In brief

To determine safety and maximum tolerated dose of brivanib alaninate when administered in combination with capecitabine, doxorubicin, ixabepilone, docetaxel and paclitaxel chemotherapy to subjects with advanced or metastatic solid tumors

Key facts

Study ID

NCT00798252

Run by

Bristol-Myers Squibb

People needed

111

Starts

2009-03-01

Expected to finish

2015-05-01

Last updated by the study team

2015-07-07

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologic/cytologic diagnosis of advanced or metastatic solid tumors
• Life expectancy >= 3 months
• Able to swallow tablets/capsules

You may not qualify if…

• Pregnant or breastfeeding women
• No more than 4 previous chemotherapy regimens in the advanced or metastatic setting (excluding prior adjuvant or hormonal / immuno / biologic antibody therapies

Where it is running

• Usc/Norris Comprehensive Cancer Center — Los Angeles, California, United States
• Dana Farber Cancer Institute — Boston, Massachusetts, United States
• Wayne State University — Detroit, Michigan, United States
• Local Institution — Edmonton, Alberta, Canada
• Local Institution — Toronto, Ontario, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.